Effects of voriconazole combined with micafungin against 101 isolates of Candida spp. and 100 isolates of filamentous fungi have been evaluated by in vitro checkerboard analysis. The combination was indifferent for 97% of the Candida isolates and synergistic for 64% of the filamentous fungi (79% for Aspergillus fumigatus).
Sigma-Aldrich Chemie GmbH, Steinheim, Germany) supplemented with 2% glucose (AppliChem GmbH, Darmstadt, Germany). For the filamentous fungi checkerboards, RPMI 1640 modified medium (Sigma Aldrich Chemie GmbH, Steinheim, Germany) without phenol red for the endpoint determination by the XTT colorimetric method, was used.
For Candida spp., MIC endpoints were determined spectrophotometrically at 540 nm (spectrophotometer MR 700; TECAN-Deutschland GmbH, Crailsheim, Germany) and recorded as the first concentration of the antifungal agent tested alone or in combination at which the turbidity was 50% less than that in the control well (17) . For filamentous fungi, the read-out was performed by recording 50% growth inhibition (MIC) using the XTT {2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazoliumhydroxide} (AppliChem GmbH, Darmstadt, Germany) colorimetric method (11) (12) (13) . Absorbance was measured spectrophotometrically at 450 (690 nm reference). MIC endpoints were determined as the first concentration of the antifungal agent tested alone or in combination at which the absorbance value was 50% less than that in the control well. For calculation purposes, off-scale MICs were converted to the next higher dilution. In vitro drug interactions were calculated on the basis of fractional inhibitory concentration (FIC) index as previously published (2, 6, 18) . Table 1 summarizes the 50% minimum inhibitory concentration (MIC 50 ) of VRC or MFG alone and the corresponding MIC 50 in combination. The median FIC indices (⌺FIC) and the resulting interaction for the 201 isolates tested are included.
Candida spp. With regard to the MIC 50 (Table 1) , high susceptibility to VRC (1, 4, 5) and MFG in single use was documented for all Candida isolates. In combination they demonstrated indifferent effects in 97% of the isolates. Due to the combination, a substantial reduction in the VRC MIC 50 was detectable, while no reduction was found for MFG. However, only three of the tested strains demonstrated synergistic effects. Johnson et al. (6) proposed that the combination of azoles (VRC) with echinocandins (MFG) has not been particularly impressive in vitro. Since echinocandins administered alone are highly active against most Candida spp. (8, 14) , the fungicidal activity may be difficult to improve in combination.
The MICs (data not shown) of VRC and MFG are so low that a possible synergism was below the detection limit of our system. The fact that there is only a significant reduction for the VRC MIC 50 emphasizes the high activity of MFG against Candida spp. The reduction of the VRC MIC 50 results from the high activity of MFG alone and is not an interaction effect. Filamentous fungi. For all filamentous isolates, respectable reductions of the MFG MIC 50 were obtained ( Table 1 ). The combination of VRC and MFG led to a significant reduction of the MIC 50 s. The interaction between VRC and MFG (Table 1) was synergistic in 64% of all molds and 79% for the A. fumigatus isolates. For S. prolificans, a pathogen with enhancing frequency of occurrence, causing various types of human infections, for three out of four tested isolates synergistic effects were observed. The majority of all indifferent FIC indices were close to the cutoff from synergism to indifference. Antagonism was not observed. In contrast to the results for the Candida spp., the combination was generally synergistic, in accordance to the investigations of Johnson et al., Manavathu et al., and Petraitis et al. (6, 9, 19) . It must be noted that clinical data from in vitro studies of the activities of the VRC-MFG combination against filamentous fungi have been poorly evaluated. According to the investigations of Manavathu et al., interactions between the two drugs were additive (9). Data from in vivo studies are sparse. An in vivo animal study demonstrated similar efficacy for monotherapy and combination therapy; however, the activity was neither enhanced nor reduced with the two-drug combination (3). Thus, current data suggest an absence of harm or a negative interaction when an azole is combined with an echinocandin for the treatment of invasive aspergillosis (3, 7) . The discrepancies of the activity between in vitro and in vivo studies have to be further investigated. For the most important clinical pathogen, A. fumigatus, we observed almost 80% synergistic effects. In conclusion, the combination of VRC and MFG was synergistic in vitro against filamentous fungi including Scedosporium spp. and F. solani. The relative lack of toxicity of both antifungals makes them an attractive option as add-on therapy. Clinical studies to investigate the effectiveness of MFG combined with VRC are warranted. This study was supported by an unrestricted grant of Pfizer, Karlsruhe, Germany. VRC was kindly provided by Pfizer (New York, N.Y.), while MFG was kindly provided by Astellas Pharma Inc., Tokyo, Japan.
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